The objective of this study for newly diagnosed acute promyelocytic Leukemia (APL) was to evaluate the efficacy of an intensified double induction chemotherapy including high dose ara-C (HD) and all-trans retinoic acid (ATRA) followed by consolidation and 3 years maintenance therapy. In contrast to APL studies stratifying therapy according to pretreatment white blood cell (WBC) count o and X10 Â 10 9 /l (low/intermediate and high risk according to the Sanz score), our patients received uniform therapy. From 1994 to 2005, 142 patients (age, 16-60 years) were enrolled. In the low/intermediate (n ¼ 105) vs high (n ¼ 37) WBC group, the rates of complete remission were 95.2 vs 83.8%, of induction death were 4.8 vs 16.2% (P ¼ 0.05) and of molecular remission were 87.5 vs 91.3% (P ¼ 1). Long-term overall survival was 84.4 vs 73.0% (P ¼ 0.12), event free survival was 78.3 vs 67.3% (P ¼ 0.11), relapse free survival was 82.1 vs 80.0% (P ¼ 0.83) and the cumulative incidence of relapse was 7.4 vs 11.4% (P ¼ 0.46). No relapse or death occurred after 4.7 years. ATRA and intensified chemotherapy including HD ara-C followed by prolonged maintenance therapy reduced the relapse risk in high risk patients. Pretreatment WBC count X10 Â 10 9 /l count was no relevant prognostic factor for relapse.
Introduction
All-trans retinoic acid (ATRA) and anthracycline-based chemotherapy is highly effective in newly diagnosed acute promyelocytic leukemia (APL). [1] [2] [3] Using this treatment approach, a joint study from the PETHEMA and GIMEMA cooperative groups has shown that the level of pretreatment white blood cell (WBC) count is the main factor associated with relapse, and a predictive model (Sanz score) allows the distinction between low risk of relapse (WBC count o10 Â 10 /l) and high risk (WBC count X10 Â 10 9 /l). 4 The association of higher initial WBC counts with a higher relapse rate was also reported for ATRA and combination chemotherapy in standard dose. [5] [6] [7] [8] Current efforts focus on the reduction of the relapse rate, in particular in the high WBC group, which still exceeds 26%, if potent drugs such as high dose (HD) ara-C or ATO are not incorporated. 2, [5] [6] [7] [8] [9] Data of recent studies strongly support a role of both drugs. [9] [10] [11] [12] [13] The present APL study of the German AML Cooperative Group (AMLCG) was started in 1994 after the approval of ATRA. The study design was based on the results of patients with APL included in the randomized AML study of the AMLCG before the advent of ATRA. In APL patients below 60 years, with intensified double induction therapy (TAD/HAM; n ¼ 11) incorporating HD ara-C, TAD consolidation and 3 years monthly maintenance therapy, the relapse free survival (RFS) rate was 70% after 9 years as compared with 19% with double induction therapy without HD ara-C (TAD/TAD; n ¼ 17) (P ¼ 0.02). 14, 15 On the basis of these results, ATRA was incorporated in the TAD/HAM regimen of the chemotherapy study.
Our regimen differs from others in particular by the intensity of the chemotherapy that is combined with ATRA including HD ara-C and by the prolonged maintenance chemotherapy. The uniform therapy allows the comparison of treatment effects in subgroups of APL, which is not possible, when risk adapted therapy is used. We present here the long-term results of this study.
Patients and methods

Objectives of the study and eligibility criteria
The objective of the study was to assess the clinical and biological effects of an intensified chemotherapy regimen including HD ara-C and ATRA in newly diagnosed APL. Eligibility criteria were cytogenetic or molecular confirmation of the diagnosis APL, age 16-60 years, no other antecedent or concomitant malignancy, no cardiac contraindication against anthracyclines and written informed consent. Patients 460 years were treated less intensively and are not included in this report. In accordance with the Declaration of Helsinki, the protocol was approved by the Research Ethics Board of each participating center. The immediate confirmation of the diagnosis APL by morphological, cytogenetic and/or molecular characterization of the leukemic cells in central laboratories was mandatory. All clinical and laboratory data were centrally registered.
Therapy
The chemotherapy regimen was adopted from AML protocols of the German AMLCG, which start with a drug and time intensified induction therapy.
14 The treatment consisted of simultaneous ATRA and double induction (TAD/HAM) chemotherapy including HD ara-C, one cycle of consolidation chemotherapy (TAD) and 3 years monthly maintenance chemotherapy.
Induction therapy
The ATRA dose was 45 mg/m 2 /day until complete hematological remission (CR) or for a maximum of 90 days. The second induction course (HAM) was scheduled on day 21 after the start of the first cycle (TAD) independent of peripheral cytopenia. According to the protocol, the start of HAM was delayed in case of infection, cardiac failure NYHA III and IV or other nonhematological toxicity grades III and IV. If CR was reached after TAD, HAM was given as an additional consolidation course.
Chemotherapy. TAD: 6-Thioguanine (6-TG) 100 mg/m 2 every 12 h, days 3-9, ara-C 100 mg/m 2 by continuous intravenous infusion, days 1-2, thereafter 100 mg/m 2 every 12 h, days [3] [4] [5] [6] [7] [8] daunorubicin (DNR) ATRA. ATRA and TAD were started simultaneously in patients with initial WBC counts X5 Â 10 9 /l or with the microgranular M3 (variant form; M3v) according to the protocols of the European APL group. 6, 16 In patients with WBC counts o5 Â 10 9 /l, ATRA was started before chemotherapy to improve or prevent the coagulopathy. In patients with significant coagulopathy (fibrinogen level o1.5 g/l or prolonged prothrombine time 41 s.d.), TAD was started after normalization of the prothrombine time and of fibrinogen, or after 14 days at the latest. Patients without coagulopathy received pretreatment with ATRA for 1 week. If the WBC count was increased to 46 Â 10 9 /l, 10 Â 10 9 /l, 15 Â 10 9 /l by days 5, 10 and 15 of ATRA treatment, respectively, chemotherapy (TAD) was added. 6, 16 The APL differentiation syndrome was diagnosed, according to Frankel et al. 17 At suspicion or manifestation of the syndrome, i.v. dexamethasone was administered at a dose of 10 mg twice daily and ATRA was temporarily discontinued until symptoms had resolved.
Consolidation and maintenance therapy
TAD consolidation therapy started 2 to 4 weeks after CR. Each monthly maintenance course consisted of ara-C 100 mg/m 2 every 12 h subcutaneously, days 1-5 and, either DNR 45 mg/m 2 , days 3 and 4 (course 1) or 6-TG 100 mg/m 2 every 12 h, days 1-5 (courses 2 and 4) or cyclophosphamide 1 g/m 2 i.v., day 3 (course 3), and then restarting the sequence with DNR (course 5). After a cumulative DNR dose of 540 mg/m 2 , DNR was replaced by 6-TG. If the nadir of the neutrophils was o0.5 Â 10 9 /l and/or of the platelets o20 Â 10 9 /l after two consecutive maintenance courses, all antileukemic drugs were reduced to 50%. Further dose reductions to 25% were performed in case of repeated cytopenia reaching the respective nadirs.
Supportive therapy
Treatment of coagulopathy during the induction phase was based on platelet support, and fresh frozen plasma, fibrinogen and/or cryoprecipitate to maintain the platelet count 450 Â 10 9 /l and the fibrinogen level 41.5 mg/l. Oral antimicrobial prophylaxis consisted of amphothericin B, cotrimoxazol and colistinsulfate.
Molecular monitoring
Bone marrow aspiration for morphological evaluation was mandatory after induction and consolidation and every 3 months during maintenance therapy and thereafter according to individual needs. Reverse transcriptase polymerase chain reaction (RT-PCR) test of PML/RARA was recommended at each bone marrow biopsy, when the study was started. From the year 1997, molecular monitoring after induction and consolidation and every 3 months during maintenance therapy was mandatory. 18 The RT-PCR was performed as reported earlier.
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Definitions and endpoints
The CR was defined according to the National Cancer Institute criteria, 20 and molecular remission as negative PML/RARA nested RT-PCR (sensitivity 10 À4 ). Molecular relapse had to be confirmed by nested RT-PCR in two marrow samples taken 2 to 4 weeks apart. Induction death was defined as death o7 days after completion of the first induction course (early death) or death during treatment induced bone marrow hypoplasia (hypoplastic death). Overall survival (OS) was calculated from the start of induction therapy until death, event free survival (EFS) was calculated from the start of therapy until nonachievement of remission or relapse or death. RFS was counted from the date of CR until relapse or death in remission whichever occurred first. The cumulative incidence of relapse (CIR) was calculated from the date of CR until relapse.
Statistical analysis
Comparison of the CR rates and failures was evaluated by Fisher's exact test. Continuous variables where compared using Wilcoxon test. Distributions of time to event variables were estimated by the Kaplan-Meier method. Comparisons were based on the log-rank test. Cumulative incidences were calculated according to Gooley et al. 21 All P-values reported are two-sided. Potential prognostic factors were evaluated by the Cox proportional hazard model. 22 In all estimates, in which the event 'relapse' was considered as an endpoint, hematological and molecular relapse were each counted as events. 23 The analysis of the data reported here was on 15 January 2008. All calculations were done using SAS-Software (version 9.1) licensed to the University Hospital of Mü nster, Germany. /l) died immediately from bleeding before therapy could be started. Ten patients were excluded according to the protocol (concomitant or antecedent malignancy: n ¼ 4, contraindication against anthracyclines: n ¼ 2, protocol violation due to misdiagnosis as AML-M2 or -M4: n ¼ 3, withdrawal of informed consent: n ¼ 1).
Results
Patient characteristics
The initial data of the 142 evaluable patients are shown in Table 1 . In all cases, APL was genetically confirmed by cytogenetics (n ¼ 132) or by RT-PCR (n ¼ 125) or by both (n ¼ 115). Applying the Sanz score, the patients were separated in two groups according to pretreatment WBC count o10 Â 10 9 /l (n ¼ 105, corresponding to low and intermediate risk) and X10 Â 10 9 /l (n ¼ 37, corresponding to high risk). The data of both subgroups are compared in Table 1 . In patients with high WBC count, a significantly higher frequency of M3v, of the BCR3 isoform, of coagulopathy, and a lower platelet count were seen.
Induction therapy Drug delivery. The induction therapy consisted of ATRA and TAD in all 142 patients. In all, 131 patients received the second induction cycle (HAM). Nine patients had previously died during or after the first cycle. In two patients, HAM was omitted due to severe complications during the first cycle. In both patients, treatment was continued with the consolidation and maintenance therapy. The median time to start of HAM was 26 days (range, 21-60), with exception of one patient who erroneously received HAM on day 13. The delay of the second course was performed for reasons defined in the protocol. In 32 patients, a CR was documented before the start of HAM.
According to the protocol, ATRA and chemotherapy were started simultaneously in 47 (33%) patients with M3v or initial WBC counts X5 Â 10 9 /l. In 86 patients (60%), ATRA was started before chemotherapy by a median of 7 days (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . On the basis of center's decision, in nine patients (7%), who all entered CR, ATRA was started 1 to 8 days after TAD, because of very high WBC counts (n ¼ 3), or because APL was misdiagnosed as an other AML subtype (n ¼ 6), which was corrected by the central laboratories. The median ATRA duration of the patients, who entered CR, was 48 days (range, 6-90 days, including 10 patients with ATRA o20 days).
Results of induction therapy. Hematological CR was reached in 92.3% of patients after a median of 55 days . Induction death occurred in 7.7% (n ¼ 9 during or after TAD, n ¼ 2 after HAM). No resistance was observed. There Table 1 Patients characteristics at study entry Side effects. In Table 4 , the major side effects are shown. The APL differentiation syndrome occurred in 21.1% of patients High dose ara-C in newly diagnosed APL E Lengfelder et al between days 2 and 29 of ATRA therapy (median day 6). In all patients, ATRA was temporarily discontinued (median duration 5 days, range . No reappearance of the syndrome occurred after restart of ATRA. Other ATRA-related symptoms (skin dryness, pseudotumor cerebri, hypercholesterolemia and hepatotoxicity) occurred rarely, but led to the termination of ATRA in four patients. Other adverse effects WHO grade X3 were: fever or infection in 42.6%, diarrhea in 18.5%, hepatotoxicity in 12.3% and hemorrhage in 18% of patients. Bleeding occurred more frequently during the first induction cycle (P ¼ 0.001) and in patients with higher initial WBC counts (P ¼ 0.03).
Consolidation and maintenance therapy
Consolidation therapy was administered in 89.8% (114 of 127) of living patients and was omitted in 13 cases due to severe side effects during induction. Two patients died after consolidation (Table 3) . Side effects WHO grade X3 were: infections (7.8%), hepatotoxicity (1.8%), cardiotoxicity (0.9%) and nephrotoxicity (0.9%). Maintenance therapy was started in 87.2% of living patients (109 of 125). In 25 (20%) cases, maintenance was prematurely terminated between course 1 and 27 (median after course 6). Reasons for omission or termination were: patient's refusal (n ¼ 13), physician's decision after severe infections (n ¼ 10), prolonged neutropenia between courses (n ¼ 8), intolerance of ara-C (n ¼ 3), hepatotoxicity (n ¼ 3), cardiac failure, pancreatic disease, chronic hepatitis or vasculitis in one patient each.
After consolidation therapy, 81 of 85 (95.3%) tested patients were in molecular remission with no significant difference according to the initial WBC count ( Table 2) . Three of the four PCR positive patients converted to negative after the first maintenance cycles. The fourth patient remained positive and relapsed hematologically after 7 months in CR. In total, of the 131 patients who entered hematological CR, in 114 patients the molecular response could be assessed and 113 (99%) patients reached a molecular remission. Seventeen patients were never tested.
Outcome Long-term results. At the time of the last analysis in January 2008, the median observation time was 6.0 years (1 day to 12.6 years). The OS of all patients was 81.8% and the CIR was 8.3%. The detailed data of OS, EFS, RFS and CIR are shown in Table 2 and in Figures 1-4a . No event occurred after 4.7 years. Of 24 total deaths, 17 deaths were observed during or after induction or after consolidation (Table 3) . Seven patients died during maintenance therapy or thereafter, two from relapse and five in CR of APL. Nine patients relapsed (two molecular and seven hematological relapses). All patients entered second remission. No extra medullary relapse was observed. Four patients (2.8%) developed MDS/secondary AML. In each case, a relapse of APL was cytogenetically and molecularly excluded. Two of these four patients are in remission after allogeneic transplantation and two died from secondary AML being in CR of APL.
Comparison according to the initial WBC count. The comparison of the groups with WBC counts o10 Â 10 9 /l and X10 Â 10 9 /l is shown in Table 2 and Figures 1-4b . The figures of OS and EFS reflect the higher rate of induction death of the high WBC group without reaching statistical difference (P ¼ 0.12 and P ¼ 0.11, respectively). The RFS was nearly equal (P ¼ 0.83). The CIR in the low vs high WBC groups was 7.4 vs 11.4% (P ¼ 0.46). Assigning the relapses of the WBC group o10 Â 10 9 /l to low and intermediate risk according to Sanz score, 3% relapses (1 of 33 patients) occurred in the low, and 6.9% (5 of 72 patients) in the intermediate risk group. No other threshold of the WBC could be defined to separate prognostic groups concerning RFS and CIR in our study. 21 
Discussion
The data indicate a high antileukemic efficacy of our regimen independent of the initial WBC count resulting in a long-term survival rate of 81.8% of the total patients. A low relapse rate was observed in the high risk patients and in low/ intermediate risk patients without significant difference between both groups.
Our protocol design is characterized by a drug and time intensification of the chemotherapy adopted from AML therapy.
14 HD ara-C and mitoxantrone are effective drugs in relapsed/refractory AML and APL. 24, 25 For time intensification, the second induction cycle was administered after a median Table 4 Toxicities WHO Grade X3 and APL differentiation syndrome according to therapy and initial WBC count All patients WBC o10 Â 10 9 /l WBC 10 Â 10 9 /l or more However, no clear definition exists on the exact equivalence doses of DNR, idarubicin or mitoxantrone. In two reports, a dose equivalence between 50 mg DNR and approximately 10 mg idarubicin or mitoxantrone was suggested. 26, 27 The administration of HD ara-C in the early phase of our therapy seems the most striking difference to all other regimens, suggesting that the inclusion of HD ara-C has a relevant impact on the low relapse rate in the high risk groups. However, this study is a single arm study, as are the majority of APL studies. Hence, the contribution of the different treatment elements cannot be separated. The advantages or disadvantages of the double induction chemotherapy causing long cytopenia and hospitalization and high costs and of the prolonged and relatively intensive maintenance therapy, remain difficult to assess and are a matter of discussion. The most appropriate dose of ara-C is under investigation, and may depend on the study design, in particular on combination and dosage of anthracyclines and other antileukemic drugs, and on the total ATRA dose. Data of recent studies published in abstract form suggest, that lower doses of ara-C are effective, when combined High dose ara-C in newly diagnosed APL E Lengfelder et al with high doses of anthracyclines and repeated administration of ATRA. 9, 13 With our protocol, a low relapse rate (CIR) of 8.3% was achieved in all risk groups, 11.4% in the high and 7.4% (P ¼ 0.46) in the low WBC group. In patients with WBC count o10 Â 10 9 /l, the PETHEMA reported a CIR at 5 years of 3% in the low and of 8% in the intermediate risk group compared with 26% in the high risk patients without ara-C. 2 In the APL 2000 trial, the CIR at 3 years was 9.9% in the high risk group treated with HD ara-C vs 14.3% in the low/intermediate risk patients treated with standard dose ara-C. 11 However, both studies included less intensively treated patients over 60 years and used shorter maintenance therapy, which reduces the comparability to our data. Concerning our study, we could not define any other WBC limits for the separation of prognostic groups with the limitation that only a difference of approximately 20% and more could be detected with a reasonable power with our patient numbers. 21 No CNS or other extra medullary relapse occurred so far indicating a protective effect of ara-C, which passes the blood/ brain barrier. A reduction of CNS relapses by ara-C was also suggested in other studies. In the APL 2000 study including ara-C, no CNS relapse was seen among 16 relapses. For comparison, in the LPA99 study of the PETHEMA without ara-C, four CNS relapses were observed among 33 relapsed patients. High dose ara-C in newly diagnosed APL E Lengfelder et al
The rate of secondary MDS/AML was 2.8%. For comparison, the European APL group reported a rate of 0.97% among 617 patients in CR after a median follow-up of 51 months. In a report of 77 patients treated at a single Italian center, the respective rate was 6.5% including patients, who had received etoposide and/or alkylating agents. 28, 29 In our study, cyclophosphamide as part of maintenance therapy might have contributed to the development of secondary MDS/AML.
The rate of induction death of 7.7% is in the range of other studies. 2, [5] [6] [7] [8] 11 Patients with WBC counts X10 Â 10 9 /l had a higher risk of death due to fatal bleeding, as to be expected. 5, [30] [31] [32] The APL differentiation syndrome was diagnosed in 21.1% of our patients, which is in the range of other reports. [33] [34] [35] [36] Possibly, the timing of ATRA and chemotherapy has contributed to the relatively high rate, as 60% of our patients received pretreatment with ATRA over a period of 7 days on average before the chemotherapy was started, as similarly observed by others. 34, 35 The high rate of severe infections leading to death in CR after induction in four patients is a disadvantage of our protocol. This seems particularly important in the low/intermediate risk patients, in whom excellent results can be achieved with less intensive therapy. 2 In conclusion, our study is the earliest and to our knowledge unique APL study incorporating ATRA and HD ara-C in the induction therapy. The long-term data confirm and extend initial results on 51 patients published earlier. 19 The relapse rate of 11.4% after 10 years is less than half compared with the data of the literature for high risk APL treated without HD ara-C. 2, 6, 8, 9 Figure 3 Relapse free survival. (a) Of all patients (n ¼ 131), who entered remission and (b) according to initial white blood cell count o or X10 Â 10 9 /l (P ¼ 0.83). Tics indicate the last follow-up of the patients without events. Events were hematological or molecular relapse or death in remission, whichever occurred first.
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The results of our study indicate that the risk profile of APL is influenced by the therapy. With our regimen, the initial WBC count was no relevant prognostic factor for relapse. Similar observations were made, when ATO was included in frontline therapy of APL. 10 It is of particular interest for the future, in how far it will be possible to reduce the dose of chemotherapy when ATO is incorporated and whether ATO can replace HD ara-C.
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